Analysts at Jefferies have issued a report stating that the share purchase plan by the management of CStone Pharma-B (02616) underscores the company's confidence in its pipeline licensing negotiations. The firm's core asset, CS2009, demonstrates distinct advantages: a low incidence of VEGF-related adverse events and significantly improved safety for the CTLA-4 target, with excellent efficacy in non-small cell lung cancer (NSCLC) and cold tumor indications. The company plans to initiate several global multi-center Phase III pivotal trials starting in late 2026, covering NSCLC and colorectal cancer, to support global regulatory submissions and business development (BD) deals. The analysts are optimistic about CS2009's commercial and licensing potential, maintaining a "Buy" rating on CStone Pharma with a target price of HK$20, representing a potential upside of 298% from the current price.

Key Points from the Report

The planned share purchases by management and the board strongly signal their high confidence in the progress of pipeline business development. Management has indicated that the current share price is significantly undervalued, reflecting a positive view on the ongoing CS2009 (a PD-1/CTLA-4/VEGF triple-target) licensing discussions. Data presented at the 2026 American Society of Clinical Oncology (ASCO) annual meeting showed robust efficacy and favorable safety for CS2009 in NSCLC and various cold tumors, positioning it as a potential next-generation foundational immuno-oncology therapy.

Differentiated Product Safety Profile Enhances Licensing Value

CS2009's safety data is impressive. In second-line or later monotherapy for NSCLC, the incidence of Grade ≥3 treatment-related adverse events (TRAEs) was 19.3%, Grade ≥3 immune-related adverse events (irAEs) was 12.3%, and VEGF-related Grade ≥3 adverse events was only 5.3%. This addresses a key industry challenge of poor safety with previous PD-1/VEGF or CTLA-4 combination regimens. Mechanistically, its CTLA-4 target features a low-affinity design that promotes T-cell activation within tumors while avoiding excessive peripheral immune activation. The VEGF-binding structure reduces free VEGF in the body, contributing to its low-toxicity profile.

Compelling Efficacy in Non-Small Cell Lung Cancer

The efficacy data in NSCLC is convincing: (1) In second-line or later NSCLC (monotherapy, 30mg/kg, n=25): objective response rate (ORR) was 24.4%, disease control rate (DCR) was 60.0%. (2) In second/third-line NSCLC (combined with docetaxel, n=6): ORR was 66.7%, DCR was 100%. (3) In first-line NSCLC (monotherapy, PD-L1 TPS≥50%, n=16): ORR was 81.3%, DCR was 100%. (4) In first-line squamous NSCLC (combined with chemotherapy, PD-L1 low/negative expression, n=8): ORR was 75.0%, DCR was 100%.

Outstanding Efficacy in Cold Tumors

CS2009 has shown clear anti-tumor activity in several difficult-to-treat "cold" tumors, with its differentiated mechanism breaking the immunosuppressive tumor microenvironment: (1) pMMR/MSS colorectal cancer (mCRC): later-line monotherapy ORR 25.0%, DCR 87.5%; first-line combined with XELOX chemotherapy ORR 66.7%, DCR 100%. (2) Soft tissue sarcoma (STS): monotherapy ORR 33.3%, DCR 66.7% (compared to a standard later-line therapy ORR of only about 6%). (3) Non-clear cell renal cell carcinoma (nccRCC): monotherapy ORR 33.3%, DCR 100% (compared to an existing standard therapy ORR of about 14%). The clinical data confirms CS2009 can improve the immunosuppressive tumor microenvironment, benefiting patients who previously did not respond to immunotherapy.

Pivotal Phase III Trial Strategy to Accelerate Global Licensing

Building on the excellent efficacy and safety data, CStone Pharma has planned several global multi-center Phase III registration trials: (1) First-line NSCLC: CS2009 + chemotherapy vs. pembrolizumab + chemotherapy, to start in Q4 2026. (2) First-line pMMR/MSS metastatic colorectal cancer, to start in Q4 2026. (3) Second-line NSCLC (combined with docetaxel), to start in Q1 2027. (4) PD-L1 high expression (TPS≥50%) first-line NSCLC head-to-head monotherapy (CS2009 vs. pembrolizumab), to start in Q1 2027. This multi-indication, multi-pipeline trial strategy aims to advance global regulatory filings and enhance BD negotiation power. The company plans to begin regulatory discussions with the U.S. FDA starting in Q4 2026.

Rationale for the Buy Rating

The report maintains a "Buy" rating based on three core arguments: ① CS2009 is a differentiated next-generation immuno-oncology drug with potential for overall survival benefit and broad BD opportunities. ② The company's proprietary ADC technology platform forms a second growth pillar for its pipeline. ③ CStone Pharma's track record of successful past BD deals suggests the potential for securing new partnerships.

Risk Factors Identified

The report notes potential risks including clinical trial failure, increased industry competition, changes in collaborative projects, regulatory approval risks in domestic and international markets, underperformance in commercial sales, changes in reimbursement policies, and production and supply chain risks.